Researchers evaluated securitization as a financing mechanism to spread upfront development and manufacturing costs for expensive cell and gene therapies targeting orphan diseases. The analysis models pooled revenue streams, risk tranching and investor returns as a way to enable broader access and reduce single‑payer price shocks. Authors caution that securitization requires robust outcome‑based contracting, long‑term data collection and regulatory alignment, but they argue the approach could mobilize capital at scale and accelerate commercialization for curative but high‑cost modalities.